Floatz logo

Paliperidone Palmitate 3-Month Formulation

Side Effect

Consorcio Centro de Investigación Biomédica en Red (CIBER)Phase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Side Effect cohort.

Asset / SponsorPhaseRating
Velpatasvir
Alexandria University
Phase 4BB
AUTOLOGOUS CONDITIONED PLASMA
Star Spine and Sport
Phase 4BB
Sofosbuvir
Alexandria University
Phase 4BB
NEPENTHE
Hopital Lariboisière
Phase 4BB
NADROPARIN
Rijnstate Hospital
Phase 4BB

View all 37 →

Same molecule, other indications

Paliperidone Palmitate 3-Month Formulation is also rated in:

schizoaffective disorderDormant
BBB
Indicative ·
78 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
76 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →